Repression of rRNA gene transcription by endothelial SPEN deficiency normalizes tumor vasculature via nucleolar stress
Authors:
- Zi-Yan YangZYZi-Yan Yang
- Xian-Chun YanXYXian-Chun Yan
- Jia-Yu-Lin ZhangJZJia-Yu-Lin Zhang
- Liang LiangLLLiang Liang
- Chun-Chen GaoCGChun-Chen Gao
- Pei-Ran ZhangPZPei-Ran Zhang
- Yuan LiuYLYuan Liu
- Jia-Xing SunJSJia-Xing Sun
- Bai RuanBRBai Ruan
- Juan-Li DuanJDJuan-Li Duan
- Ruo-Nan WangRWRuo-Nan Wang
- Xing-Xing FengXFXing-Xing Feng
Open Access
- 16 October 2023
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 133 (20)
Abstract
Human cancers induce a chaotic, dysfunctional vasculature that promotes tumor growth and blunts most current therapies; however, the mechanisms underlying the induction of a dysfunctional vasculature have been unclear. Here, we show that split end (SPEN), a transcription repressor, coordinates rRNA synthesis in endothelial cells (ECs) and is required for physiological and tumor angiogenesis. SPEN deficiency attenuated EC proliferation and blunted retinal angiogenesis, which was attributed to p53 activation. Furthermore, SPEN knockdown activated p53 by upregulating noncoding promoter RNA (pRNA), which represses rRNA transcription and triggers p53-mediated nucleolar stress. In human cancer biopsies, a low endothelial SPEN level correlated with extended overall survival. In mice, endothelial SPEN deficiency compromised rRNA expression and repressed tumor growth and metastasis by normalizing tumor vessels, and this was abrogated by p53 haploinsufficiency. rRNA gene transcription is driven by RNA polymerase I (RNPI). We found that CX-5461, an RNPI inhibitor, recapitulated the effect of Spen ablation on tumor vessel normalization and combining CX-5461 with cisplatin substantially improved the efficacy of treating tumors in mice. Together, these results demonstrate that SPEN is required for angiogenesis by repressing pRNA to enable rRNA gene transcription and ribosomal biogenesis and that RNPI represents a target for tumor vessel normalization therapy of cancer.Keywords
Funding Information
- the National Natural Science Foundation (31730041, 31671523, 82003110, 81900870)
- the Key Research and Development Program of Shaanxi Province (2023-YBSF-118)
This publication has 73 references indexed in Scilit:
- Ribosomal RNA Gene Transcription Mediated by the Master Genome Regulator Protein CCCTC-binding Factor (CTCF) Is Negatively Regulated by the Condensin ComplexJournal of Biological Chemistry, 2013
- Molecular mechanisms and clinical applications of angiogenesisNature, 2011
- Integrative genomic analysis of human ribosomal DNANucleic Acids Research, 2011
- CTCF regulates the local epigenetic state of ribosomal DNA repeatsEpigenetics & Chromatin, 2010
- Mediation of CTCF transcriptional insulation by DEAD-box RNA-binding protein p68 and steroid receptor RNA activator SRAGenes & Development, 2010
- Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesisNature, 2010
- Intergenic transcripts originating from a subclass of ribosomal DNA repeats silence ribosomal RNA genes in transEMBO Reports, 2009
- Signaling to p53: Ribosomal Proteins Find Their WayCancer Cell, 2009
- Requirement of Split ends for Epigenetic Regulation of Notch Signal-Dependent Genes during Infection-Induced Hemocyte DifferentiationMolecular and Cellular Biology, 2009
- Generation of a conditional knockout allele for mammalian Spen protein Mint/SHARPGenesis, 2007